XML 152 R38.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenue (Disaggregation of Revenue by Geographical Region) (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2023 | Apr. 01, 2022 | Dec. 31, 2022
Disaggregation of Revenue [Line Items] |  |  |
Revenue | $ 7,167 | $ 7,688 |
Recurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 5,386 | 5,898 |
Nonrecurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,781 | 1,790 |
North America |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 3,022 | 3,354 |
Western Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,708 | 1,828 |
Other developed markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 353 | 378 |
High-growth markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 2,084 | 2,128 |
Environmental & Applied Solutions |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue |  |  | $ 4,800
Operating segments | Biotechnology |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,864 | 2,216 |
Operating segments | Biotechnology | Recurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,511 | 1,801 |
Operating segments | Biotechnology | Nonrecurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 353 | 415 |
Operating segments | Biotechnology | North America |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 618 | 782 |
Operating segments | Biotechnology | Western Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 647 | 707 |
Operating segments | Biotechnology | Other developed markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 79 | 85 |
Operating segments | Biotechnology | High-growth markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 520 | 642 |
Operating segments | Life Sciences |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,709 | 1,666 |
Operating segments | Life Sciences | Recurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,039 | 1,037 |
Operating segments | Life Sciences | Nonrecurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 670 | 629 |
Operating segments | Life Sciences | North America |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 708 | 738 |
Operating segments | Life Sciences | Western Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 364 | 328 |
Operating segments | Life Sciences | Other developed markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 128 | 137 |
Operating segments | Life Sciences | High-growth markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 509 | 463 |
Operating segments | Diagnostics |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 2,376 | 2,644 |
Operating segments | Diagnostics | Recurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 2,112 | 2,370 |
Operating segments | Diagnostics | Nonrecurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 264 | 274 |
Operating segments | Diagnostics | North America |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,124 | 1,306 |
Operating segments | Diagnostics | Western Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 420 | 524 |
Operating segments | Diagnostics | Other developed markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 117 | 124 |
Operating segments | Diagnostics | High-growth markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 715 | 690 |
Operating segments | Environmental & Applied Solutions |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 1,218 | 1,162 |
Operating segments | Environmental & Applied Solutions | Recurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 724 | 690 |
Operating segments | Environmental & Applied Solutions | Nonrecurring revenue |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 494 | 472 |
Operating segments | Environmental & Applied Solutions | North America |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 572 | 528 |
Operating segments | Environmental & Applied Solutions | Western Europe |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 277 | 269 |
Operating segments | Environmental & Applied Solutions | Other developed markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | 29 | 32 |
Operating segments | Environmental & Applied Solutions | High-growth markets |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Revenue | $ 340 | $ 333 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=dhr_RevenuefromContractwithCustomerMeasurementRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dhr_RevenuefromContractwithCustomerMeasurementNonrecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=dhr_WesternEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=dhr_OtherdevelopedmarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=dhr_HighgrowthmarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_EnvironmentalAppliedSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_BiotechnologySegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dhr_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |